Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...
Hosted on MSN1d
Most Americans who want to lose weight don’t want to take GLP-1 drugs like Wegovy and Zepbound, new survey saysYet despite the ubiquitousness of injectable drugs indicated for people with obesity—such as Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide)—most Americans wouldn’t take them, ...
The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from ...
Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...
These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates ...
Lilly CEO Dave Ricks in Wednesday’s third-quarter earnings call acknowledged that the company is at the mercy of wholesaler ...
Wall Street analysts were impressed by data showing competitive rates of weight loss for Viking’s therapy, but shares in the ...
Size means little in light of this company's prospects.
Lilly last week reported a rare $1.5 billion sales miss for its injectable obesity drug Zepbound and diabetes medicine Mounjaro combined, raising concerns among investors that demand might be cooling ...
Eli Lilly ( LLY) is planning to advertise its blockbuster weight loss drug, Zepbound, for the first time next month. Despite ...
Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback